期刊文献+

小细胞肺癌83例临床分析

原文传递
导出
摘要 目的 观察小细胞肺癌综合治疗疗效及副作用。方法 83例小细胞肺癌患者分别采用放疗结合化疗、手术加化疗、单纯化疗治疗;化疗方案为足叶乙甙联合卡铂,对不同分期及不同治疗方案的疗效进行比较,用Kaplan-Meier进行生存分析。结果 83例中总的完全缓解(CR)率为60.0%,全组患者生存时间7.60个月,中位生存期16.5个月,无进展生存期1~60个月,中位无疾病进展生存期10个月;1、2、3、4、5年生存率分别为71.4%,24.7%、16.8%、13.4%、4.5%。结论 小细胞肺癌患者治疗应采用放化疗综合治疗。化疗方案以卡铂、足叶乙甙(CE)为主,治疗4—8个周期。
出处 《中国综合临床》 北大核心 2007年第4期341-342,共2页 Clinical Medicine of China
  • 相关文献

参考文献6

  • 1Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent [ J ]. Br J Cancer,2000,83 ( 1 ) : 8.
  • 2Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposlde and eisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis[ J]. Lung Cancer, 2000, 30( 1 ) :23-26.
  • 3Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high dose and standard dose etoposide and eisplatin chemotherapy in patients with extensive stage small cell lung cancer[J]. J Clin Oneol, 1994,12(10) :2022-2034.
  • 4Skarlos DV, Samantas E, Kosmidls P, et al. Randomize comparison of etopeside-cisplatin vs etopeside-carboplatinan irradiation in small cell lung cancer:A Hellenic Cooperative Oncology Group Study[J]. Ann Oncol, 1994, 5(7) :601.
  • 5程颖,柳影,靳凤艳.小细胞肺癌综合治疗进展[J].吉林医学,2006,27(7):705-708. 被引量:2
  • 6王惠杰,张湘茹.小细胞肺癌的治疗进展[J].癌症进展,2005,3(5):512-518. 被引量:4

二级参考文献55

  • 1陈茂森,聂立功,李楠,陈建,张红.TE方案与CE方案治疗复发性小细胞肺癌的对比研究[J].临床肿瘤学杂志,2005,10(5):479-480. 被引量:5
  • 2[1]http: ∥www. nccn. org/professionals/physician_ gls/PDF/scl.pdf
  • 3[2]Kurup A, Hanna NH. Treatment of small cell lung cancer. Crit Reviv Oncol/Hemat, 2004, 52:117
  • 4[3]Krug LM. Small cell lung cancer. In: Ginsberg RJ edited.American cancer society atlas of clinical oncology: Lung Cancer.Hamilton London BC Decker Inc, 2002
  • 5[4]Arriagada R, Pignon JP, Ihde DC, et al. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A metaanalysis of 13 randomized trials among 2, 140 patients. Anticancer Res, 1994, 14 (1B):333
  • 6[5]Murray N, Coldman A. The relationship between the thoracic irradiation timing and long-term survival in combined modality therapy of limited stage small cell lung cancer (LSCLC). Proc Am Soc Clin Oncol, 1995, 14:360 (abs)
  • 7[6]Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer. J Clin Oncol,2004, 22 (23):4837
  • 8[7]Komaki R, Allen P, Glisson B, et al. Hyperfractionated/accelerated radiation therapy (HFXRT) increased survival compared to dailt RT (GDRT) for small cell lung cancer (LSCLC)with concurrent chemotherapy (CHT). Proc Am Soc Clin Oncol, 2005, 24:Abs7158
  • 9[8]Edelman MJ, Chansky K, Gaspar LE, et al. Phase Ⅱ Trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer:Southwest Oncology Group 9713. J Clin Oncol, 2004, 22:127
  • 10[9]Mitsuoka S, Kudoh S, Takada, et al. Phase Ⅱ study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplatin in patients with limited stage small-cell lung cancer (SCLC); updated results of WJTOG9902. Proc Am Soc Clin Oncol, 2004, 23:Abs7044

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部